Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease

被引：3
作者：
Petrov, Vladimir, I [1 ]
Shatalova, Olga, V [1 ]
Gerasimenko, Anastasia S. [1 ]
Gorbatenko, Vladislav S. [1 ]
机构：
[1] Volgograd State Med Univ, Fac Adv Training Doctors, Course Clin Pharmacol & Clin Allergol, Chair Clin Pharmacol Intens Care & Resuscitat, Pavshikh Bortsov Pl 1, Volgograd 400131, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2019年 / 15卷 / 04期
关键词：
atrial fibrillation; chronic kidney disease; direct oral anticoagulants; warfarin; GLOMERULAR-FILTRATION-RATE; STAGE RENAL-DISEASE; CREATININE CLEARANCE; STROKE PREVENTION; SYSTEMIC EMBOLISM; WARFARIN; RIVAROXABAN; APIXABAN; PHARMACOKINETICS; DABIGATRAN;
D O I：
10.20996/1819-6446-2019-15-4-530-537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The purpose of this review is to examine the possibilities and prospects for the use of direct oral anticoagulants for the prevention of thromboembolic complications in patients with atrial fibrillation and chronic kidney disease. Chronic kidney disease is an independent risk factor for cardiovascular complications. Atrial fibrillation is associated with a higher risk of developing chronic kidney disease and more rapid progression of existing renal pathology. The presence of chronic kidney disease in atrial fibrillation on the one hand leads to an increased risk of thromboembolism, and on the other - to an increased risk of bleeding when using anticoagulants. The standard for the prevention of thromboembolic complications in atrial fibrillation, including those with concomitant renal pathology, was considered warfarin for many years. However, modern studies have shown that the use of warfarin may enhance vascular calcification in patients with chronic kidney disease, which in turn may lead to an increased risk of ischemic strokes. Analyzing clinical recommendations, randomized studies, meta-analyzes and a systematic review on the use of anticoagulants in patients with atrial fibrillation and renal pathology, revealed the advantage of using direct oral anticoagulants over warfarin at stage 1-3 of chronic kidney disease. Data on the use of direct oral anticoagulants with a more pronounced renal dysfunction and in patients on dialysis is limited due to the lack of a sufficient number of large randomized studies. Due to the presence of renal clearance in all oral anticoagulants, their pharmacokinetics changes to some extent with a decrease in the glomerular filtration rate, which requires dose adjustment of drugs depending on creatinine clearance. Therefore, the use of anticoagulants for the prevention of thromboembolic complications during atrial fibrillation requires special attention in patients with chronic kidney disease.
引用
收藏
页码：530 / 537
页数：8
相关论文
共 40 条
[1]   Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin A Systematic Review and Meta-analysis [J].
Albertsen, Ida Ehlers ;
Rasmussen, Lars Hvilsted ;
Overvad, Thure Filskov ;
Graungaard, Tina ;
Larsen, Torben Bjerregaard ;
Lip, Gregory Y. H. .
STROKE, 2013, 44 (05) :1329-+
[2]   Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial [J].
Alexander, Karen P. ;
Brouwer, Marc A. ;
Mulder, Hillary ;
Vinereanu, Dragos ;
Lopes, Renato D. ;
Proietti, Marco ;
Al-Khatib, Sana M. ;
Hijazi, Ziad ;
Halvorsen, Sigrun ;
Hylek, Elaine M. ;
Verheugt, Freek W. A. ;
Alexander, John H. ;
Wallentin, Lars ;
Granger, Christopher B. .
AMERICAN HEART JOURNAL, 2019, 208 :123-131
[3]   Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation The Atherosclerosis Risk in Communities (ARIC) Study [J].
Alonso, Alvaro ;
Lopez, Faye L. ;
Matsushita, Kunihiro ;
Loehr, Laura R. ;
Agarwal, Sunil K. ;
Chen, Lin Y. ;
Soliman, Elsayed Z. ;
Astor, Brad C. ;
Coresh, Josef .
CIRCULATION, 2011, 123 (25) :2946-U81
[4]   Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis [J].
Antza, Christina ;
Doundoulakis, Ioannis ;
Akrivos, Evangelos ;
Economou, Fotios ;
Vazakidis, Polychronis ;
Haidich, Anna-Bettina ;
Kotsis, Vasilios .
SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2019, 53 (02) :48-54
[5]   Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial [J].
Bohula, Erin A. ;
Giugliano, Robert P. ;
Ruff, Christian T. ;
Kuder, Julia F. ;
Murphy, Sabina A. ;
Antman, Elliott M. ;
Braunwald, Eugene .
CIRCULATION, 2016, 134 (01) :24-+
[6]   Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF [J].
Chan, Kevin E. ;
Giugliano, Robert P. ;
Patel, Manesh R. ;
Abramson, Stuart ;
Jardine, Meg ;
Zhao, Sophia ;
Perkovic, Vlado ;
Maddux, Franklin W. ;
Piccini, Jonathan P. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (24) :2888-2899
[7]   Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis [J].
Chan, Kevin E. ;
Edelman, Elazer R. ;
Wenger, Julia B. ;
Thadhani, Ravi I. ;
Maddux, Franklin W. .
CIRCULATION, 2015, 131 (11) :972-979
[8]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[9]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[10]   The atrial fibrillation conundrum in dialysis patients [J].
De Vriese, An S. ;
Caluwe, Rogier ;
Raggi, Paolo .
AMERICAN HEART JOURNAL, 2016, 174 :111-119
1234